The government has made permanent its temporary ban on puberty blockers for under-18s, following months of uncertainty for families across the UK. The decision, announced by the Department of Health and Social Care, comes after extensive medical review and makes indefinite a restriction that has been in place since March.
The move follows comprehensive assessments by the National Institute for Health and Care Excellence (NICE) and NHS England, which found insufficient evidence supporting the safety and long-term effectiveness of these medications for children experiencing gender dysphoria. Under the indefinite ban, no new prescriptions will be issued to under-18s, whilst existing young patients will be moved to alternative care pathways where clinically appropriate.
The policy applies across England, Scotland, and Wales, with Northern Ireland expected to adopt similar measures. This creates a unified approach throughout the UK, though it represents a significant shift for families who had previously accessed these treatments through NHS services.
The Department of Health and Social Care stressed that safeguarding young people's wellbeing remains paramount, with medical decisions requiring robust clinical evidence. The Health Secretary emphasised the government's commitment to protecting vulnerable children and ensuring healthcare choices serve their best interests.
Labour has indicated support for the ban, with party representatives stating their commitment to following clinical evidence whilst ensuring children receive optimal care. This cross-party backing reflects widespread concern about prescribing powerful medications to minors without sufficient safety data.
For families affected by gender dysphoria, this policy shift means NHS services will now prioritise comprehensive support including psychological interventions and mental health care, rather than medication-based treatments for young people. The change forms part of a broader reassessment of gender identity services within the NHS, following recommendations from independent clinical reviews.